SLPI TREATED MONOCYTE INHIBITS HUMAN LYMPHOCYTE PROLIFERATION

DIEGO GUERRIERI; ROMINA M. REITERI; NANCY L. TATEOSIÁN; ANALÍA BARRO; M. JULIETA COSTA; PAULO C. MAFFÍA; XIMENA VILLALONGA; MERCEDES L. SANCHEZ; SILVIA M. ESTEIN; HUGO ESTEVA; VERÓNICA E. GARCIA; JUAN A. MAZZEI; H. EDUARDO CHULUYAN

Journal of leucocyte biology

Año: 2009

Serine Leukocyte proteinase inhibitor (SLPI) is produced by epithelial cells and isanti-inflammatory and microbicide. However, the role of SLPI on adaptive immuneresponse is not well established. We evaluated a putative correlation between SLPIlevels and lymphocyte proliferative ability. Human peripheral blood mononuclear cells(PBMCs) were treated with mitogens plus SLPI and proliferation was assessed by[3]H-thymidine uptake. SLPI plasma levels and proliferation were measured inhealthy donors (HD; n =15), chronic obstructive pulmonary disease (COPD, n =17)and lung cancer (n = 23) patients.SLPI decreased the lymphocyte proliferation induced by IL-2, avoided IkBdegradation, increased secretion of IL-4, IL-6 and IL-10 while decreased IFNγ. SLPIinhibition was not observed by depleting monocytes from PBMCs and it was restoredby adding either SLPI-pretreated monocytes or culture supernatant. Monocytestreated with SLPI, produced IL-4, IL-6 and IL-10. However, mainly IL-4 reproducedthe inhibition observed with SLPI. Furthermore, plasma SLPI concentration wascorrelated with PBMC proliferation in COPD and lung cancer patients but not in HD.Our results demonstrated that SLPI indirectly inhibits lymphocyte proliferation andTh1 cytokine secretion. Thus, plasma SLPI concentration might be used as a markerof lymphocyte proliferation to follow up the immune status.